Literature DB >> 10464335

Phospholipase A(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans.

P Sartipy1, G Camejo, L Svensson, E Hurt-Camejo.   

Abstract

The presence of a lipoprotein profile with abundance of small, dense low density lipoproteins (LDL), low levels of high density lipoproteins (HDL), and elevated levels of triglyceride-rich very low density lipoproteins is associated with an increased risk for coronary heart disease. The atherogenicity of small, dense LDL is believed to be one of the main reasons for this association. This particle contains less phospholipids (PL) and unesterified cholesterol than large LDL, and the apoB-100 appears to occupy a more extensive area at its surface. Although there are experiments that suggest a metabolic pathway leading to the overproduction of small, dense LDL, no clear molecular model exists to explain its association with atherogenesis. A current hypothesis is that small, dense LDL, because of its higher affinity for proteoglycans, is entrapped in the intima extracellular matrix and is more susceptible to oxidative modifications than large LDL. Here we describe how a specific reduction of approximately 50% of the PL of a normal buoyant LDL by immobilized phospholipase A(2) (PLA(2)) (EC 3.1.1.4) produces smaller and denser particles without inducing significant lipoprotein aggregation (<5%). These smaller LDL particles display a higher tendency to form nonsoluble complexes with proteoglycans and glycosaminoglycans than the parent LDL. Binding parameters of LDL and glycosaminoglycans and proteoglycans produced by human arterial smooth muscle cells were measured at near to physiological conditions. The PLA(2)-modified LDL has about 2 times higher affinity for the sulfated polysaccharides than control LDL. In addition, incubation of human plasma in the presence of PLA(2) generated smaller LDL and HDL particles compared with the control plasma incubated without PLA(2). These in vitro results indicate that the reduction of surface PL characteristic of small, dense LDL subfractions, besides contributing to its small size and density, may enhance its tendency to be retained by proteoglycans.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10464335     DOI: 10.1074/jbc.274.36.25913

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Phospholipase A2 catalysis and lipid mediator lipidomics.

Authors:  Varnavas D Mouchlis; Edward A Dennis
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2018-08-23       Impact factor: 4.698

2.  Association of rheumatoid arthritis disease activity and antibodies to periodontal bacteria with serum lipoprotein profile in drug naive patients.

Authors:  Aulikki Kononoff; Pia Elfving; Pirkko Pussinen; Sohvi Hörkkö; Hannu Kautiainen; Leena Arstila; Leena Laasonen; Elina Savolainen; Helena Niinisalo; Jarno Rutanen; Olga Marjoniemi; Mari Hämäläinen; Katriina Vuolteenaho; Eeva Moilanen; Oili Kaipiainen-Seppänen
Journal:  Ann Med       Date:  2020-02-10       Impact factor: 4.709

3.  Gene targeting reveals the role of Oc90 as the essential organizer of the otoconial organic matrix.

Authors:  Xing Zhao; Hua Yang; Ebenezer N Yamoah; Yunxia Wang Lundberg
Journal:  Dev Biol       Date:  2007-01-12       Impact factor: 3.582

4.  LDL phospholipid hydrolysis produces modified electronegative particles with an unfolded apoB-100 protein.

Authors:  Liana Asatryan; Ryan T Hamilton; J Mario Isas; Juliana Hwang; Rakez Kayed; Alex Sevanian
Journal:  J Lipid Res       Date:  2004-10-16       Impact factor: 5.922

5.  Endothelial lipase-modified high-density lipoprotein exhibits diminished ability to mediate SR-BI (scavenger receptor B type I)-dependent free-cholesterol efflux.

Authors:  Martin Gauster; Olga V Oskolkova; Josef Innerlohinger; Otto Glatter; Gabriele Knipping; Sasa Frank
Journal:  Biochem J       Date:  2004-08-15       Impact factor: 3.857

6.  Secretory phospholipase A2 induces dendritic cell maturation.

Authors:  Laure Perrin-Cocon; Sophie Agaugué; Frédéric Coutant; Aurélie Masurel; Sofiane Bezzine; Gérard Lambeau; Patrice André; Vincent Lotteau
Journal:  Eur J Immunol       Date:  2004-08       Impact factor: 5.532

7.  Secretory phospholipase A2 in patients with coronary artery disease.

Authors:  Luciana Moreira Lima; Maria das Graças Carvalho; Cirilo Pereira da Fonseca Neto; José Carlos Faria Garcia; Marinez Oliveira Sousa
Journal:  J Thromb Thrombolysis       Date:  2009-05-17       Impact factor: 2.300

Review 8.  Secretory phospholipase A2: a multifaceted family of proatherogenic enzymes.

Authors:  Robert S Rosenson; Michael H Gelb
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

9.  Increased hepatic cholesterol accumulation in transgenic mice overexpressing human secretory phospholipase A2 group IIA.

Authors:  Rolf Eckey; Mario Menschikowski; Peter Lattke; Werner Jaross
Journal:  Inflammation       Date:  2004-04       Impact factor: 4.092

10.  ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

Authors:  Anne Hiukka; Marcus Ståhlman; Camilla Pettersson; Malin Levin; Martin Adiels; Susanne Teneberg; Eeva S Leinonen; Lillemor Mattsson Hultén; Olov Wiklund; Matej Oresic; Sven-Olof Olofsson; Marja-Riitta Taskinen; Kim Ekroos; Jan Borén
Journal:  Diabetes       Date:  2009-06-05       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.